Effective March 1, 2026 UnitedHealthcare clarifies coverage for endovascular revascularization of lower-extremity ischemia: procedures are covered for lifestyle‑limiting Claudication only when documented impaired ADLs/work, failure of ≥12 weeks supervised or structured exercise plus guideline‑directed medical therapy and smoking cessation, and objective hemodynamic/imaging evidence (ABI ≤0.90 and ≥50% stenosis on duplex or confirmatory CTA/MRA/angiography). Retreatment for in‑stent restenosis is covered when recurrent symptoms and imaging-confirmed ≥50% stenosis are present. Endovascular treatment for CLTI remains covered as limb‑threatening care. The policy lists several unproven/not‑medically‑necessary indications (eg, non‑limb‑threatening infrapopliteal interventions, asymptomatic disease, procedures solely to prevent progression, iliac atherectomy, treatment of nonviable limbs, and endovenous femoropopliteal bypass with stent graft) and cites current guideline and trial evidence supporting these distinctions.

March 2026 Revision: Clarified Endovascular Criteria for Claudication and CLTI

This revision (effective 2026-03-01) clarifies coverage criteria for endovascular revascularization of lower extremity ischemia in non-limb-threatening Claudication and for Chronic Limb-Threatening Ischemia (CLTI). The policy explicitly states that the criteria do not apply to upper extremities and reiterates that endovascular procedures (stents, angioplasty, atherectomy) are "proven and medically necessary" for Claudication only when a set of clinical and diagnostic prerequisites are met. It also codifies that retreatment for in-stent restenosis is "proven and medically necessary" when recurrent symptoms and objective imaging-confirmed stenosis are present.

The update further enumerates specific scenarios deemed unproven and not medically necessary due to insufficient evidence (e.g., interventions for non-limb-threatening infrapopliteal disease, asymptomatic individuals, procedures intended solely to prevent progression from Claudication to CLTI, transluminal iliac atherectomy, treatment of nonviable limbs, and endovenous femoropopliteal bypass using a stent graft). These points are presented clearly within the Coverage Rationale and Instructions for Use sections of the policy.

Coverage Requirements for Claudication: Clinical and Diagnostic Thresholds

For individuals with non-limb-threatening Claudication due to atherosclerotic disease of the aortoiliac and/or femoropopliteal arteries, endovascular revascularization is covered when all enumerated criteria are met. Clinically, the individual must have impaired ability to work and/or perform activities of daily living (ADL). Conservatively, the policy requires failure of multiple therapies: at least twelve (12) weeks of Supervised Exercise Therapy or a Structured Community-Based Exercise Program, guideline-directed pharmacologic therapy (e.g., lipid-lowering, antihypertensive, antiplatelet, and/or anticoagulant therapy), and smoking cessation when applicable.

Retreatment and CLTI Coverage: Conditions for In-Stent Restenosis and Limb-Threatening Disease

Retreatment of a previously treated vessel for in-stent restenosis is addressed explicitly: it is considered "proven and medically necessary" for non-limb-threatening Claudication when the individual has recurrent symptoms, impaired ability to work or perform ADLs, and imaging demonstrating a ≥ 50% stenosis in the previously treated vessel (with the same duplex ultrasound caveat as primary interventions).

Separately, the policy affirms that endovascular revascularization procedures are "proven and medically necessary" for treating Chronic Limb-Threatening Ischemia (CLTI) with the diagnoses listed under the policy's applicable codes, reflecting the more urgent, limb-saving indication for revascularization compared with intermittent Claudication.

Explicitly Unproven / Not Medically Necessary Situations

The policy lists several circumstances where endovascular interventions for lower extremity ischemia are considered unproven and not medically necessary due to insufficient evidence. These include interventions for non-limb-threatening infrapopliteal arteries (anterior tibial, posterior tibial, peroneal), procedures in asymptomatic individuals, procedures performed solely to prevent progression from Claudication to CLTI, transluminal peripheral atherectomy of the iliac artery, treatment of nonviable limbs, and endovenous femoropopliteal bypass using a stent graft.

This delineation separates routine revascularization indications from procedures lacking evidence of clinical benefit and aligns with the policy’s emphasis on symptom burden, objective hemodynamic/imaging findings, and prior conservative management as prerequisites for coverage.

Alignment with Guidelines and Key Evidence Summaries

The policy cites contemporary guideline statements and evidence syntheses to support its criteria. It references multi-society appropriate use criteria (Bailey et al., 2019), AHA/ACC guidance (Gornik et al., 2024), and SVS recommendations (Conte et al., 2019; 2015; 2025 focused update), which emphasize initial noninvasive management (medical therapy and supervised or structured exercise) for intermittent Claudication and reserving revascularization for lifestyle-limiting symptoms despite conservative therapy. The policy also notes guideline-level cautions about infrapopliteal interventions for non-limb-threatening disease and limited support for iliac atherectomy.

Evidence summaries included in the policy (systematic reviews and the BEST-CLI randomized trial) are used to frame comparative outcomes between endovascular and surgical approaches—e.g., similar mortality and major amputation in aggregate reviews, lower reintervention rates after bypass in some analyses, and mixed findings in BEST-CLI depending on cohort and available conduit—supporting the policy’s differentiation between Claudication and CLTI indications and its emphasis on objective criteria and prior conservative care.

OpenPayer